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Abstract: Methicillin-resistant Staphylococcus pseudintermedius (MRSP) constitutes an emerging health
problem for companion animals in veterinary medicine. Therefore, discovery of novel antimicrobial
agents for treatment of Staphylococcus-associated canine infections is urgently needed to reduce
use of human antibiotics in veterinary medicine. In the present work, we characterized the
antimicrobial activity of the peptoid D2 against S. pseudintermedius and Pseudomonas aeruginosa, which
is another common integumentary pathogen in dogs. Furthermore, we performed a structure–activity
relationship study of D2, which included 19 peptide/peptoid analogs. Our best compound D2D,
an all D-peptide analogue, showed potent minimum inhibitory concentrations (MICs) against canine
S. pseudintermedius (2–4 µg/mL) and P. aeruginosa (4 µg/mL) isolates as well as other selected dog
pathogens (2–16 µg/mL). Time–kill assays demonstrated that D2D was able to inhibit MRSP in
30 min at 1× MIC, significantly faster than D2. Our results suggest that at high concentrations D2D
is rapidly lysing the bacterial membrane while D2 is inhibiting macromolecular synthesis. We probed
the mechanism of action at sub-MIC concentrations of D2, D2D, the L-peptide analog and its retro
analog by a macromolecular biosynthesis assay and fluorescence spectroscopy. Our data suggest that
at sub-MIC concentrations D2D is membrane inactive and primarily works by cell wall inhibition,
while the other compounds mainly act on the bacterial membrane.
Keywords: antimicrobial; peptide; peptoid; mode of action; canine infections; methicillin-resistant
Staphylococcus pseudintermedius; Pseudomonas aeruginosa
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1. Introduction
Canine skin infections and otitis constitute the number one reason for antimicrobial prescription in
dogs. Staphylococcus pseudintermedius is the main canine pathogen associated with these conditions [1].
In recent years, the spread of methicillin-resistant Staphylococcus pseudintermedius (MRSP), such as
the epidemic clone sequence type ST68 in North America and ST71 in Europe, has become a serious
therapeutic challenge in small animal medicine [2,3]. Also, human infections associated with MRSP
ST71 have been reported [4]. Although less frequent than S. pseudintermedius, Pseudomonas aeruginosa is
another pathogen associated with canine pyoderma as well as infections of the canine ear canal [5].
This pathogen may also constitute a treatment challenge due to its intrinsic resistance to several
antimicrobial agents. The shortage of antimicrobial options against resistant integumentary infections
stresses the need for new antimicrobials specifically for veterinary medicine [6].
Antimicrobial peptides (AMPs), also known as host defense peptides, are present in a broad
variety of multicellular organisms [7]. As they contain both hydrophobic and positively charged
residues, AMPs amphipatic nature provides a preferential cell selectivity towards bacterial cells rather
than eukaryotic cells [8]. To date, AMPs are mostly believed to act through a fast, membrane-disrupting
bactericidal mechanism [9]. Whereas peptides have an undeniable potential to become a base for the
next generation of antimicrobial agents, they exhibit a number of limitations, such as low bioavailability
due to their susceptibility to proteases [10]. In order to overcome such stability issues, several classes
of synthetic peptides, or peptidomimetics, which mimic the structure and function of AMPs, have been
introduced in the past decades [11]. These classes of molecules retain the antimicrobial activity and
mechanism of action of AMPs, while gaining stability to proteases. Peptoids, constitute a class of the
peptidomimetics that exhibit promising antimicrobial activity and protease stability [12,13]. Notably,
when introduced into the peptide, peptoid residues can improve the antibacterial profile of the parent
peptide alongside its biostability, yielding promising peptide–peptoid hybrids [14–16]. Though AMPs
and their mimics often display high systemic toxicity issues [17], they, alone or in combination with
a conventional antibiotic have potential to become therapeutics for topical application, e.g., to treat
bacterial skin infections.
We have previously described a promising antimicrobial peptoid, D2, which is active against
MRSP and P. aeruginosa, resistant to plasma proteases and hepatic clearance in vitro, and is suitable for
topical administration to treat superficial pyoderma [18]. In the present study, we investigated the
structural features responsible for antimicrobial activity of D2 by (a) performing Gly-scan to analyze
the residues crucial for activity; (b) investigating the effects of single substitution in order to increase
activity; (c) exploring the effect of the peptoid backbone by exchanging L- and D- amino acids for
their peptoid counterparts; (d) testing against a panel of canine pathogens; (e) performing circular
dichroism studies; (f) measuring the biosynthesis rate of macromolecules and bacterial proton motive
force to elucidate the mode of action.
2. Results and Discussion
2.1. MIC Distribution of D2 and Time–Kill Kinetics
The potential of D2 (Figure 1) to treat infections topically has been studied previously, including
release from formulation and in vitro ADME (absorption, distribution, metabolism, and excretion)
properties [18]. In the present study, we further evaluated the antimicrobial activity of D2 against a
panel of 50 S. pseudintermedius and 50 P. aeruginosa isolates from canine infections (Figure S2 Supporting
information). The MICs ranged from 1.56 to 3.12 µM and 3.12 to 12.5 µM, respectively.
D2 time–kill experiments were done using the clinical MRSP strain C22963 (Figure 2). At 1× and
2× MIC, we observed log 1.5 and log 2.7 reductions after 6 h.
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We observed regrowth after 24 h (d t o shown).
The MICs of D2 are comparable with previous literature reports on peptides targeting MRSP.
Molchanova et al. describ d a number of diffe nt α-peptide/β-peptoid hybrids, which were active
against MRSP (2–8 µg/mL) as well as other pathogenic bact ria r levant to human and v t rinary
medicine [15]. In continuation of the above s udy, the same authors investig ted the ffect of
fluorination, oligomer length, a d end-group modification [19]. These peptidomimetics were tested
against S. pseudinter edius isolates, with MICs ranging from 0.5 µg/mL to 4 µg/ L. The compounds
were al o potent against Escherichia coli, P. aeruginosa, and Methicillin-resistant Staphylococcus a reu
(MRSA). The antimicrobial a tivity of six peptides ag inst clinical isolat of Methicillin-susceptible
Staphylococcus pseudintermedius (MSSP) and MRSP from infected dogs was also investigated y
Mohamed et al. [20]. The most potent compounds had a MIC50 and MIC90 of 1 and 2 µM, respectively.
Very recently, we reported a peptide–peptoid hybrid, B1, which showed potent MICs against a number
of canine S. pseudintermedius (2–4 µg/mL) and P. aeruginosa (8–16 µg/mL) isolates [21]. This compound
inhibited MRSP (C22963) and P. aeruginosa in less than 30 min at 8× MIC as shown by time–kill kinetics.
The peptoid D2 showed slower killing kinetics compared to B1 and antimicrobial peptide and peptoid
analogues of B1. Finally, another peptide, AMP2041, showed LD90 values of 0.5–8 µg/mL against
P. aeruginosa strains derived from dog otitis [22].
2.2. Structure–Activity Relationship (SAR) Study of D2
In order to understand the structural features of D2 responsible for its activity, we have performed
a structure–activity relationship study on its backbone. First, we performed a Gly-scan by substituting
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sequentially every peptoid residue with a Gly amino acid, to elucidate the effect of every side chain on
the activity of D2. We identified the side chain in position 5 as not essential for antimicrobial activity
and proceeded substituting this residue with other residues.
2.2.1. Glycine-Scan of D2
Glycine-scan technique corresponds to the systematic replacement of each residue by glycine.
Such structure–activity relationship study provides information on the functional role of the individual
residues in the peptoid. This includes the contribution of the single peptoid residue side chain to the
biological activity of D2. Furthermore, hydrophobic and electrostatic side-chain interactions as well as
H-bonds with the target may be probed [23]. A total of 8 glycine analogs of D2 (1–8) were synthesized
with systematic substitutions of glycine in every position (Table 1).
Table 1. Structures, antimicrobial activity (MIC, µg/mL) and hemolytic activity (% at 150 µM) of eight
analogues of D2 resulting from Gly-scan.
ID SEQUENCE a MIC HA f
MSSP b MRSP c SA d PA e
D2 Nlys Nlys N1Nal N4MePhe Nlys N1Nal Nlys NNle 2–4 4 8 16 24
1 Gly Nlys N1Nal N4MePhe Nlys N1Nal Nlys NNle 4 4 16 32 42
2 Nlys Gly N1Nal N4MePhe Nlys N1Nal Nlys NNle 16 8 16 64 48
3 Nlys Nlys Gly N4MePhe Nlys N1Nal Nlys NNle 64 64 >64 >64 56
4 Nlys Nlys N1Nal Gly Nlys N1Nal Nlys NNle 64 32 >64 >64 40
5 Nlys Nlys N1Nal N4MePhe Gly N1Nal Nlys NNle 4 4 32 16 25
6 Nlys Nlys N1Nal N4MePhe Nlys Gly Nlys NNle >64 >64 >64 >64 6
7 Nlys Nlys N1Nal N4MePhe Nlys N1Nal Gly NNle 8 4 16 16 85
8 Nlys Nlys N1Nal N4MePhe Nlys N1Nal Nlys Gly 8 8 32 32–64 49
a Products synthesized as C-terminal amides; b Methicillin sensitive Staphylococcus pseudintermedius (26916);
c Methicillin resistant Staphylococcus pseudintermedius, (C22963); d Staphylococcus aureus (ATCC 29213); e Pseudomonas
aeruginosa (ATCC 27853); f Percentage of hemolysis at 150 µM.
The glycine scan revealed that the bulky hydrophobic aromatic groups such as
1-naphthalenemethyl in position 3 and 6, and 4-methylbenzyl in position 4 were crucial for
antimicrobial activity, as their removal was accompanied by a shift in MIC values to 64 µg/mL or
higher against all tested strains. Notably, Gly to Nleu substitution in position 8 had a less detrimental
impact on antimicrobial activity. The loss of antimicrobial activity for these analogs is not surprising,
considering that hydrophobicity is one of the crucial parameters for antimicrobial activity of AMPs
and peptidomimetics. The ability of AMPs to lyse red blood cells, also referred to as hemolysis,
is often used as an indication of toxicity [24]. Decrease in the hydrophobicity is often associated
with a simultaneous decrease in hemolytic activity; however, for the NMePhe to Gly and Nle to Gly
substitutions in positions 4 and 8, respectively, the opposite effect was observed, with an approximately
two-fold increase in HA%. Surprisingly, the substitutions of N1Nal in positions 3 and 6 led to opposite
effects on the HA% (56% and 6% respectively).
The NLys substitution in position 2 resulted in a 2–4-fold loss of activity against all strains tested,
and a 2-fold increase in HA%. This suggests a high importance of a cationic residue in this position.
The NLys substitutions in position 1, 5, and 7 had a subtler impact on antimicrobial activity: no activity
loss was observed against MSSP and MRSP, but a slight decrease of activity against P. aeruginosa and
S. aureus was observed for all three analogs. NLys substitution in the position 1 resulted in a 2-fold
increase in hemolysis at 150 µM, while no effect was observed for the NLys in position 5. Interestingly,
the NLys substitution in position 7 increased the HA at 150 µM dramatically to 85%.
2.2.2. Substitutions in Position 5
The glycine scan revealed that the NLys residue in position 5 was non-essential for both
antimicrobial and hemolytic activity, suggesting it to be a potential site for optimization. Hence,
a series of peptoid analogues of D2 were designed, where NLys residue was substituted with four
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different types of side chains (9–12) in position 5. Four side chains were chosen to represent a wide
spectrum of hydrophobicity, from short aliphatic side chains such as methyl to bulkier aromatic groups
such as 4-methylbenzyl and 1-napthalenmethyl. An analog with a polar NEtOH group as side-chain
was also included (12), as seen in Table 2.
Table 2. Effect of single substitutions in position 5 on antibacterial (MIC, µg/mL) and hemolytic activity
(% at 150 µM) of D2.
ID SEQUENCE a MIC HA f
MSSP b MRSP c SA d PA e
D2 Nlys Nlys N1Nal N4MePhe Nlys N1Nal Nlys NNle 2–4 4 8 16 24
9 NMe 4 4 16 32 16
10 N4MePhe 8 8 8 16 69
11 N1Nal 8 8 8 16 87
12 NEtOH 8 8 32 >64 5
a Products synthesized as C-terminal amides; b Methicillin sensitive Staphylococcus pseudintermedius (26916);
c Methicillin resistant Staphylococcus pseudintermedius, (C22963); d Staphylococcus aureus (ATCC 29213); e Pseudomonas
aeruginosa (ATCC 27853); f Percentage of hemolysis at 150 µM.
For all tested compounds, little to no effect in antimicrobial activity was observed compared to the
lead peptoid D2. The analogue with methyl side chain (9) maintained MIC values of 4 µg/mL against
both MSSP and MRSP. Analogues 10 and 11 with bulky side chains showed a slight increase in MIC
from 4 to 8 µg/mL. No significant change in selectivity was observed against S. aureus or P. aeruginosa.
We found that the side chain modifications in position 5 had a more profound impact on the
hemolytic activity. A clear correlation between increasing hydrophobicity and hemolytic activity was
observed for all analogs, with peptoid 11 being the most hemolytic compound. Interestingly, a short
polar aliphatic side chain in position 5 of analogue 12 caused a reduction in the hemolytic activity to
5%, however at a slight cost of antimicrobial activity. Since little or no change in antimicrobial activity
was observed for all analogs, we speculate that the hydrophobicity threshold for D2 was reached.
2.3. Modification of Backbone Nature of D2
The presence of peptoid residues in the backbone of D2 could be another contributing factor
for its antimicrobial and hemolytic activity. To investigate the extent of this effect, we generated
the corresponding L- and D- peptide analogues of D2 (D2L and D2D). Furthermore, we generated
an L-retro-peptide analogue (with inverted sequence) and a series of peptide–peptoid hybrids by
systematically replacing charged or hydrophobic peptoid residues with corresponding D-residues.
All three peptide analogs of peptoid D2 were designed either using only L-amino acids (D2L) or
D-amino acids (D2D), and added a reversed sequence using only L-amino acids (D2R) (Table 3).
Table 3. Structures, antimicrobial (MIC, µg/mL), and hemolytic activity (% at 150 µM) of L- (D2L), D-
(D2D), retro- (D2R), and peptide–peptoid hybrid analogues (13–16) of D2.
ID SEQUENCE a MIC HA f
MSSP b MRSP c SA d PA e
D2 Nlys Nlys N1Nal N4MePhe Nlys N1Nal Nlys NNle 2–4 4 8 16 24
D2L Lys Lys 1Nal Phe Lys 1Nal Lys Nle 16 8 32 16 35
D2D lys lys 1nal phe lys 1nal lys nle 1–4 4 4 4 35
D2R Nle Lys 1Nal Lys Phe 1Nal Lys Lys 16 4 32 32–64 23
13 Nlys Nlys N1Nal N4MePhe lys 1nal lys nle 4 4 8 8 34
14 lys lys 1nal phe Nlys N1Nal Nlys NNle 4 4 16 64 5
15 Nlys Nlys 1nal phe Nlys 1nal Nlys nle 4 4 32 >64 6
16 lys lys N1Nal N4MePhe lys N1Nal lys NNle 4 4 16 64 4
a Products synthesized as C-terminal amides; b Methicillin sensitive Staphylococcus pseudintermedius (26916); c
Methicillin resistant Staphylococcus pseudintermedius, (C22963); d Staphylococcus aureus (ATCC 29213); e Pseudomonas
aeruginosa (ATCC 27853); f Percentage of hemolysis at 150 µM.
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Both L-peptides D2L and D2R displayed a general loss of activity against all bacterial strains,
most notably against MSSP (with a 4–8-fold decrease in antimicrobial activity). Interestingly, the analog
D2D containing only D-amino acids demonstrated a 2–4-fold improvement in activity against both
S. aureus and P. aeruginosa, while maintaining activity against MSSP and MRSP. Peptides D2L and
D2D exhibited similar hemolytical activities (35% at 150 µM). Retro-peptide D2R showed hemolytic
activity (23% at 150 µM) comparable to that of the lead peptoid D2 (24%). Although the initial aim
of the project was to optimize D2 against MRSP, the increased broad-spectrum activity observed for
analog D2D made this peptide an interesting lead compound.
2.4. C- and N-Substituted Analogs
Many studies have found that interruption of the hydrophobic surface and/or disruption of
amphipathic secondary structure primarily impacts the toxicity of AMPs to eukaryotic cells, while
having more moderate effects on their antimicrobial activity [25]. As the next step, in the effort to
reduce the hemolytic activity of the analog D2D, four peptide/peptoid hybrids were designed by
systematically replacing peptoid residues with the corresponding D-amino acids. In analogs 13 and 14,
C-terminal and N-terminal residues of peptoid D2 were replaced with D-amino acids, respectively.
In analogs 15 and 16, the hydrophobic or hydrophilic residues were replaced with the corresponding
D-amino acids, respectively (Table 3).
Introduction of D-amino acids in the sequence resulted in maintaining activity against
Gram-positive bacteria. Accordingly, the MIC values against S. pseudintermedius remained unaltered
with all the substitution tested. The substitution of D-amino acids with peptoids in the full N-terminal
moiety of 14 did not show any effect on the activity on S. aureus, while the C-terminal substituted 15
and the hybrids 16 lost activity against S. aureus (MICs of 16 to 32 µg/mL). Three peptoid–peptide
hybrids (14, 15, and 16) lost activity against P. aeruginosa with MICs increasing from 16 µg/mL to
64 µg/mL or more. With regard to hemolysis, while analogs 14, 15, and 16 showed no detectable
hemolytic activity at 150 µM, hybrid 13 demonstrated hemolysis comparable to the analog D2D (34%),
the all D-amino acid peptide version of D2.
2.5. Antimicrobial Activity of the Best Analogue D2D
2.5.1. Time–Kill Kinetics of D2D
In the light of the results above, D2D was chosen for time kill kinetic studies against a clinical
MRSP strain (C22963, Figure 3). The all-D peptide showed killing to bacterial levels below the detection
threshold at 1× MIC in 30 min. Furthermore, a clear concentration-dependent bacterial killing was
observed, as are often seen for cationic AMPs [11].
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2.5.2. Antimicrobial Activity of D2 and D2D against Canine Pathogens
We screened the antimicrobial activity of D2 and the analogue D2D against a number of canine
pathogens (Table 4). These included Acinetobacter baumannii, Escherichia coli, Enterococcus faecalis, and
Klebsiella pneumoniae isolated from wounds, Corynebacterium auriscanis associated with canine otitis
externa [26], the nosocomial pathogen Enterococcus faecium [27], the endocartitis-causing Streptococcus
canis [28], and Proteus mirabilis [29]
Table 4. Spectrum of antimicrobial activity of D2 and D2D against a broad range of canine isolates,
including Gram-positive and Gram-negative species.
Bacteria D2 D2D
Acinetobacter baumannii, 27065, 16 D1, dog, wound, 2010 >64 16
Corynebacterium auriscanis, 31551, 54 C6, dog, ear, 2013 2 2
E. coli, 30235, 23 A6, dog, wound, 2012 64 4
Enterococcus faecalis, 27404, 17 C7, dog, wound, 2011 >64 8
Enterococcus faecium, 30951, 24 C1, dog, ear, 2013 16 4
Klebsiella pneumoniae, 26233, 11 H5, dog, wound, 2010 >64 8
Proteus mirabilis, 25178, 9 A4, dog, ear, 2009 >64 >64
Pseudomonas aeruginosa (26314, 12 C5, dog, urine, 2010) 32 8
D2 only showed activity against C. auriscanis (MIC = 2 µg/mL) and E. faecium (MIC = 16 µg/mL).
MICs for D2D were ranging from 2–16 µg/mL, except for P. mirabilis (64 µg/mL). In the majority of
cases, D2D showed a 2- to 8-fold better activity than D2. Our MIC data for D2D are fully comparable
with previous literature reports [21].
2.5.3. MSSP vs. MSSA
Very recently, we reported two structurally related peptides, which showed preferential activity
against S. pseudintermedius (MIC = 2–16 µg/mL) over S. aureus (MIC = 32–64 µg/mL) [21]. Similarly, in
this study, to assess the degree of selectivity for S. pseudintermedius, D2 and D2D were tested against
a collection of S. aureus and MSSP strains (Table S2). However, D2 and D2D retained comparable
activity against multiple clinical strains of MSSA (1–2 µg/mL) and MSSP (2–8 µg/mL).
2.6. Circular Dichroism of Selected Analogues of D2
In order to investigate the solution folding of the D2 peptide analogues in Table 3, circular
dichroism (CD) spectroscopy was applied. The compounds D2L, D2D, D2R, and the analogs 13–16
were studied in 10 mM phosphate buffer at pH 7.4 with and without addition of 50% (v/v) TFE
(2,2,2-trifluooethanol) (Figure S2). The far UV CD spectra were expected to have a strong influence
from the aromatic groups, and the spectra of D2L do bear a resemblance to the far UV signals observed
for N-acetyl-L-1-naphtylalanine ester [30], which has a positive component at 240 nm, a negative at
220 nm and again a positively signed signal below 200 nm. Thus, the all L- peptide D2L showed
a positive band above 225 nm, two negatively signed bands at 208 and 215 nm, and changes to a
positive signal below 200 nm. Interestingly, the co-solvent TFE—a simple membrane model, which is
known to induce α-helical folding—changed the peptide conformation and yielded much stronger
CD signals (Figure S4). If D2R—the retro sequence with L-amino acids—is compared to D2L, it
appears that peptide backbone conformation does play a role for the CD spectra. We thus interpreted
the spectral changes in TFE to correspond to an increase in folded conformers, likely with α-helical
content. Spectral overlap with aromatic side-chain transitions may via sign-cancellation partially
obscured the amide n-π* band at 222 nm that is characteristic of α-helical folding. As expected, the
all D-enantiomer D2D, showed a mirrored spectral signature to the D2L. The presence of the peptoid
residues disrupted the peptide structure as hybrid analogs 13, 14, 15, and 16 all showed spectra with
Molecules 2019, 24, 1121 8 of 16
limited secondary-structure signatures, and with no significant differences appearing by changing
solvent from aqueous buffer to 50% TFE (Figure S4).
2.7. Investigating the Mechanism of Action by Emission DiSC3(5) Fluorescence and Macromolecule
Biosynthesis Assay
Cationic antimicrobial peptides act cooperatively, accumulating on the negatively charged
membrane. When a threshold concentration is reached, AMPs disrupt the membrane, causing
membrane thinning and creating transient pores at intermediate concentrations [31]. However, AMPs
can translocate into bacterial cells through the transient pores [32] at sub-MIC concentrations without
causing lethal membrane disruptive events and interacting with intracellular targets [33].
In this study, we probed the mechanism of action of D2 and selected analogues using fluorescence
spectroscopy and macromolecule biosynthesis assay at sub-inhibitory concentrations. Most of the
peptides may induce cell lysis at higher concentration but our aim was to identify the novel mode
of action if that exist beyond cell lysis, and for that use of sub-MIC concentration is very important
The relative change of membrane proton motive force (PMF) is often measured by fluorescence
spectroscopy using a fluorophor, which is concentrated in the bacterial membrane [34]. If the AMP is
membrane active at sub-inhibitory concentrations, the probe is released into the assay medium. AMP
inhibition of DNA and cell wall synthesis are probed by measuring the rate of incoorporation of the
radiolabeled precursors 3H-thymidine and 3H-Glucosamine hydrochloride, respectively [35].
2.7.1. Growth Curve Analysis
First, we performed growth curve analysis using the well-characterized MRSP ST71 strain E104,
which is resistant to a number of antibiotics [36]. Growth curve experiments showed decrease of
cell optical density (OD) over time indicating cell lysis by D2, D2L, D2D, and D2R at the MIC
(Figure S3 Supporting Information). Only minor cell growth inhibition was observed at sub-MIC
concentrations. A well-characterized antimicrobial peptide, nisin, was used as control. Nisin interacts
with the lipid II layer and consequently inhibits cell-wall synthesis as shown in a number of biophysical
studies, including NMR [37], isothermal titration calometry [38], and dye leakage experiments [39].
Increased concentrations of nisin inhibited proportionally the growth of E104, both at sub-MIC and
MIC concentrations.
2.7.2. Emission DiSC3(5) Fluorescence Spectroscopy
In this study, the DiSC3(5) probe was used to assess the effect of D2 and its structural analogues
D2L, D2D, and D2R on cytoplasmic membrane depolarization. DiSC3(5) is a cationic carbocyanine
dye, which accumulates on negatively charged membrane, translocates into lipid membrane with
a distribution dependent on plasma and mitochondrial membrane potential [40]. Altered emission
profile of DiSC3(5) measured via fluorescence spectroscopy indicates membrane depolarization caused
by proton motive force dissipation, ATP production and/or pore formation. The increment of DiSC3(5)
fluorescence of labeled cells resulting from its leakage upon addition of antimicrobial agents is usually
measured over time [40]. The protonophore carbonyl cyanide metachlorophenyl hydrazone (CCCP)
is used as positive control, which rapidly dissipates PMF increasing proton permeability, alters
both membrane proton gradient and transmembrane electric potential and decreases cellular ATP
content [41]. Based on the MIC and growth analysis results, sub-lethal concentrations of D2 and
selected analogues were chosen to perform DiSC3(5) fluorescence and macromolecule biosynthesis
studies. D2L and D2R showed the strongest effect on PMF followed by the peptoid D2 and D2D
(Figure 4). The peptoid D2 is nearly as active as D2L and D2R, suggesting that cationicitiy and
hydrophobicity is important for membrane interaction. Nisin does not have any effect on PMF.
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Figure 4. Effect on membrane depolarization at sub-MIC concentrations (0.5× MIC) of the positive
control CCCP, D2, D2D, D2L, D2R, and the negative control nisin. (A) Intensity of fluorescence
(arbitrary units) is reported as function of the time; (B) change of fluorescence after 1.6 min for each
compound ± SEM (n = 2).
2.7.3. Macromolecule Biosynthesis Assay
The effect on DNA and cell wall synthesis was investigated after 20 min of incubation of MRSP
E104 with the precursors 3H-thymidine and 3H-glucosamine hydrochlo ide, respectively, as previously
reported by Ling et al. [42]. Following macromolecule pre ipitat on, radioa tivity was counted using
scintillation fluid. Incorporation of 3H- or 14C-labeled thymidine has been used to investigate DNA
replication and transcriptiona activity during the cell cycle [43]; 3H-glucosamine hydrochloride has
been used in a mode of ac stu y for the antimicrobial peptide plectasin, which targets the ell wall
precursor lipid II [44].
AMPs have been reported to interact with DNA [45], being both cationic and hydrophobic.
The most active compound in the DNA biosynthesis rate assay (Figure 5a) was D2D (37% inhibition)
followed by D2L (17% reduction in DNA replication). The compounds D2 and D2R did not show
any significant activity (<5%). For nisin, a 45% reduction was observed. Our finding that nisin shows
no membrane depolarisation but is the most significant at inhibiting macromolecular synthesis is in
contrast with previous reports. At the concentrations used in this study, nisin is known to bind to lipid
II and forms pores [46] effectively operating through a receptor-mediated membrane lysis mechanism.
D2D demonstrated the most pronounced effect on cell wall synthesis (39%, Figure 5b) followed by
D2L (31%), D2 (28%), and D2R (22%).
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Figure 5. Effect of sub-MIC concentration of AMPs on macromolecule biosynthesis. (A) Effect on DNA
and (B) cell wall synthesis in cells treated with sub-MIC concentrations (0.5× MIC) of D2D, D2L, and
D2R after 20 min of incubation. The peptide nisin was used as control. Data are represented as means
of two repeated experiments ± SEM.
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The data reported in this study suggest that D2D has an intracellular mode of action. Not only
is D2D the compound with the lowest activity on PMF among all the tested compounds (Figure 4),
but at sub-MIC concentration it also inhibits DNA and cell wall synthesis (Figure 5a,b). This is in
agreement with previous reports that some AMPs may inhibit DNA and cell wall synthesis, including
indolicidin [45].
Our finding that the D-peptide is more active that the L-enantiomer is not surprising.
The difference underlying this reason is unclear; however it could be attributed to a higher resistance
of the D- analogue to bacterial proteases or to increased affinity towards bacterial membrane targets.
Since D2D is approximately four-fold more active than its enantiomer D2L, we cannot rule out that
D2D is binding to a chiral receptor and then causing membrane lysis/pore formation. In a recent study,
the activity and mode of action of a sapesin B analog, KLKLLLLLKLK-NH2, have been compared
to its corresponding all-D analogue [47]. The D-peptide showed a significantly higher antimicrobial
activity against S. aureus (1 vs. 16 µg/mL). The authors found that this is due to its increased affinity
to peptidoglycan, and suggested that the peptide chiral components of the peptidoglycan could be
involved in this preferential interaction. Similar results were reported by Oddo et al. [48]. It is likely
that the fast kill kinetics showed by D2D could be attributed to a combined effect on the membrane
and of interaction with DNA and cell wall synthesis, which might be related to a higher affinity of
D2D for macromolecules.
We observed that the retro-L-peptide has approximately the same MIC and membrane activity
as the L-peptide. However, the L-analogue inhibits DNA and cell wall synthesis to a higher degree,
indicating the distribution of residues in the chain may play a significant role in the activity.
The membrane activity of the full peptoid D2 appears to be between the D- and L-peptide form.
The peptoid did not show any effect on DNA synthesis and its effect on cell wall synthesis was
comparable to the peptide D2L. This suggests that backbone hydrogen bonding is important in DNA
synthesis inhibition. Furthermore, the different conformational flexibility of peptoids compared to
peptides may influence their interaction with the bacterial membrane. For example, it has been reported
that flexible non-natural antimicrobial peptidomimetics act differently on the bacterial membrane
compared to their structured analogues [49].
The results obtained in this study about D2 are in agreement with a peptide–peptoid hybrid, B1,
we reported recently [21]. This peptidomimetic also did not inhibit DNA synthesis and showed cell
wall synthesis inhibition.
Insertion of even a single peptoid residue in an antimicrobial peptoid may change the activity
and mode of action. For example, using membrane depolarization, dye leakage experiments
and confocal data, Jeong et al. demonstrated that peptoid-containing analogues of Piscidin-1
(FFHHIFRGIVHVGKTIHRLVTG) penetrated the cell membrane of S. aureus, indicating the presence of
intracellular targets. In contrast, the corresponding peptides permeabilized specifically the bacterial
cell membrane [50]. Finally, two short linear peptidomimetics with a modular structure of peptoid
residues resembling tryptophan and lysine have been recently reported by Mojsoska et al. [51]. Both
peptoids caused membrane permeabilization in E. coli, to different degrees between the two molecules.
3. Materials and Methods
3.1. Materials
Disposable 5-mL polypropylene reactors fitted with a PTFE filter were acquired from Thermo
Fisher Scientific (Hvidovre, Denmark). Tentagel S RAM resin, TFA, piperidine, and Fmoc-protected
L- and D-amino acids were purchased from Iris-Biotech GmbH (Marktredwitz, Germany) Primary
amines, bromoacetic acid, DIEA and Triisopropylamine were from Sigma-Aldrich (Søborg,
Denmark). HOAt (1-Hydroxy-7-azabenzotriazole) and HATU (1-[Bis(dimethylamino)methylene]-
1H-1,2,3-triazolo [4,5-b]pyridinium 3-oxid hexafluorophosphate, N-[(Dimethylamino)-1H-1,2,3-
triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexa-fluorophosphate N-oxide)
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were from GL Biochem (Shanghai, China). DMF (dimethylformamide, synthesis grade), DCM
(dichloromethane, optical grade), MeCN (acetonitrile, optical grade) were from VWR (Copenhagen,
Denmark). All reagents and solvents were used without further purification.
3.2. Synthesis
The peptides D2D, D2L, and D2R were synthesized manually on a Tentagel S RAM resin
(0.22 meq/g) in a syringe equipped with a fritted filter. Fmoc amino acids were coupled using HATU,
HOAt and DIEA (4:4:8 eq) in DMF for 2 h. Deprotection was accomplished with 20% DMF in piperidine
(3 × 4 min). The peptoid D2 was synthesized on a TentaGel S RAM resin using the submonomer
approach. Peptoid residues were coupled using bromoacetic acid and DIC (1:1, 10 equiv.) in DMF for
30 min followed by amine (40 equiv.) displacement in DMF for 2 h. Peptoid hybrid synthesis was
done using a combination of the submonomer approach and Fmoc SPPS described above. Following
synthesis, the product was cleaved from the resin with TFA:H2O:TIS (95:2.5:2.5), precipitated in
ether and lyophilized. Peptide purification was achieved by preparative reverse-phase HPLC system
consisting of WatersTM (Milford, MA, USA) 600 Pump, In-line Degasser, 600 Controller and 2996
Photodiode Array Detector, the column used was a WatersTM XSelect® Peptide CSH C18 OBDTM,
5 µm, 19 × 250 mm with H2O:ACN gradient. The appropriate fractions were concentrated and
lyophilized. Purity was determined by analytical reverse-phase HPLC system consisting of WatersTM
717 plus Autosampler, in-line degasser AF, 600 controller and 2996 photodiode array detector, the
column used was a WatersTM SymmetryTM C18, 5 µm, 4.6 × 250 mm on an acetonitrile-water gradient.
Finally, the products were characterized by matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (Bruker Microflex, Bremen, Germany), using α-cyano-4-hydroxycinnamic acid
as matrix.
3.3. Antimicrobial Susceptibility Testing
To explore the antimicrobial activity of the library of peptides and peptidomimetics, they were
tested against Acinetobacter baumannii, Corynebacterium auriscanis, Escherichia coli, Enterococcus faecalis,
Enterococcus faecium, Klebsiella pneumonia, Proteus mirabilis, and Pseudomonas aeruginosa. Bacteria grown
on agar plates for 18 h at 37 ◦C were diluted to ~1 × 108 CFU/mL in Mueller–Hinton broth (MHB).
Two-fold serial dilutions of peptides and peptidomimetics in MHB II were inoculated with bacteria
to achieve a final concentration of 5 × 105 CFU/mL in polypropylene 96 U-well microtiter plates
(Almeco, Esbjerg, Denmark), followed by incubation at 37 ◦C in ambient air for 18 h. The MIC values
were determined as the lowest concentration showing no visible bacterial growth. Experiments were
performed twice (in technical triplicates) on two different days.
3.4. Time–Kill Kinetics
The time–kill experiments of D2 against the methicillin-resistant S. pseudintermedius strain C22963
were performed using an in-house protocol adopted and modified from Blondeau et al. [52]: the
bacterium was grown overnight on a blood agar plate. The next day, an inoculum was transferred
to MHB and incubated for 2 h at 37 ◦C to reach exponential growth phase. The inoculum was then
adjusted to achieve cell density of 105 CFU/mL in MHB using a nephelometer, and the antimicrobial
agent was added in culture tubes in 2-fold concentrations from 0.5 to 4 times the MIC. Aliquots
were removed at 1 h intervals up to 6h and spotted in triplicate on blood agar plates, and incubated
overnight at 37 ◦C. Colonies were counted and CFU per mL was calculated.
3.5. Hemolysis of Red Blood Cells
Hemolysis was done as described by Oddo et al. [48]. Briefly, 75 µL of peptide in PBS was
mixed with 75 µL of a 0.5% red blood cell (RBC) suspension in PBS, and incubated for 1 h at 37 ◦C.
The hemoglobin release was then measured at 414 nm and normalized, using mellitin as positive
control and PBS as negative control. Experiments were done in triplicates.
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3.6. Growth Curves
Performance of Growth Curves in High-Throughput
The effect of D2 or analogues or nisin on the growth of MRSP strain E104 was evaluated using
BioScreen (Oy Growth Curves Ab LTd, Helsinki, Finland). Freshly grown culture of E104 was diluted
to OD 0.2 at 600 nm, supplemented with increased concentration of antimicrobials and distributed in a
100 well honeycomb micro-plate with volume 100 µL. The plate was incubated for 6 h at 37 ◦C with
continuous shaking. The OD600 of each micro-culture was measured and recorded every 15 min after a
5 s pause of shaking in automatic mode. Recorded OD was plotted against time to prepare the growth
curves. Experiment was performed twice and one representative result was presented.
3.7. Circular Dichroism (CD) Spectroscopy
CD spectroscopic experiments were used to study the solution structure of analogues in phosphate
buffer (10 mM, pH 7.4) and in 50% 2,2,2-trifluoroethanol (TFE) using a Jasco J-815 spectropolarimeter
in Hellma QS cuvettes with pathlength 1.00 mm. Stock solutions of 1 mg/mL were prepared from
lyophilized analogs in 50 mM Na2HPO4, pH 7.4 and were diluted to appropriate concentrations of
~0.1 mg/mL in 10 mM buffer, or same concentration in 50% TFE (v/v). The spectra of the analogues
were recorded in 10 mM buffer and 50% (v/v) TFE at room temperature. The measurements were
conducted in the far UV range from 250 to 190 nm with a scan rate of 20 nm/min at 1 nm bandwidth,
and a time constant of 0.5 s. The resulting spectra were the average of six separate recordings. Blank
samples of 10 mM buffer, respectively 10 mM buffer with 50% (v/v) TFE, were recorded and subtracted
from the relevant sample spectra. The CD spectra were normalized with regard to the UV absorbance at
280 nm (relative to the D2D analog). The UV absorbance data were measured on a Shimadzu UV-3600
UV–vis–NIR spectrophotometer using a 10 mm Hellma quartz cuvette. Finally, the CD spectra were
smoothed with a five-point Savitzky–Golay filter in Jasco spectra analysis and the CD signal at 250 nm
was adjusted to zero.
3.8. Fluorescence Assay
Studying Bacterial Membrane Potential by Measuring DiSC3(5) Fluorescence
Freshly grown E104 cells with OD 0.2 at 600 nm were labeled with 1 µM 3,3-
dipropylthiadicarbocyanine iodide [DiSC3(5)] (Sigma-Aldrich, Søborg, Denmark) in MHB.
The fluorescence spectra of fluorophore-labeled cells were plotted using the LS-50B luminescence
spectrometer (PerkinElmer, Waltham, MA, USA) at excitation/emission wavelengths 546 nm/573 nm
using time drive application of FLWINLAB software. After reading initial stable emission spectra
of DiSC3(5), labeled cells were exposed with D2 or analogues or nisin or protonophore CCCP by
directly injecting the concentrated solution of agent to the cuvette, and the change of fluorescence over
time was recorded until emission spectra reached to stability. The increment of DiSC3(5) fluorescence
upon addition of antimicrobials or CCCP (FUafter-exposure – FUbefore-exposure) was calculated
and plotted in addition to raw fluorescence spectra. Experiment was performed twice and average
fluorescence change was plotted with standard deviation.
3.9. Macromolecule Biosynthesis Assay
Assay to Measure the Macromolecule Biosynthesis Rate
Macromolecules (DNA and cell wall) biosynthesis rates were measured using strain MRSP E104
following a protocol adapted from Ling et al. [42]. Briefly, overnight culture of E104 was diluted 1:100
in MHB and freshly grown up to OD 0.2 at 600 nm. Grown cells were pelleted down by centrifugation
and then resuspended in fresh MHB medium followed by incubation for 20 min on a dry heat-bath
with D2 or analogues or nisin and radiolabeled precursor: (50 µCi) 3H-Thymidine (PerkinElmer)
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and (5 µCi) 3H-glucosamine hydrochloride per mL for DNA and cell wall, respectively. A positive
control without antimicrobials was maintained that corresponds to 100% synthesis rate. After 20 min
of incubation, samples were precipitated with equal volume of cold 30% trichloroactic acid (TCA
Sigma, Søborg, Denmark) on ice. After 15 to 30 min of incubation on ice, precipitates were filtered on a
membrane filter and subsequently washed twice with cold 15% TCA and twice with cold water using
a vacuum manifold. Next, filters were air dried overnight and then moved to 10 mL scintillation vials.
Finally, 3 mL scintillation fluid was added to each vial and 3H count was taken in Beckman Coulter
LS6500 liquid scintillation counter for 1 min. The radioactive counts of the control samples with no
antimicrobial exposure were considered to have 100% precursor incorporation and macromolecule
synthesis. The percentage rates of macromolecule synthesis in the antimicrobial-exposed samples were
calculated compared to control. Each experiment was performed twice with a technical replicate, and
the average rates of synthesis were plotted.
4. Conclusions
In this study, we characterized the antimicrobial activity of the peptoid D2 against the canine
pathogen S. pseudintermedius. We optimized its activity via a structure–activity study, involving
Gly-scan single residue substitutions, exploring the effect of the peptoid backbone by converting D2
to the corresponding peptides. The most potent analog, D2D, containing all D-amino acids, showed
excellent killing kinetics against MRSP and activity against a panel of canine pathogens. Fluorescence
spectroscopy and a macromolecule biosynthesis assay revealed that D2D at sub-MIC concentrations
inhibited cell-wall synthesis, rather than disrupted bacterial membrane. This study confirms the
potential of peptides and peptidomimetics as veterinary antimicrobial agents, and the crucial role of
backbone nature in the discovery process of peptide-based therapeutics.
Supplementary Materials: The following are available online, Figure S1: Analytical HPLC Chromatograms after
Purifications; Figure S2: MIC Distribution; Figure S3: Growth Curves; Figure S4: Growth Curves; Table S1: Table
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and S. intermedius.
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